Browse communities
Browse communities
Presenting a webinar?

Corning Scientific Seminar Series

Channel profile:

Training for Life Science Researchers

The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Subscribers (4,785)
Tips and Techniques for Serum-free Expansion of hMSCs Brian Posey Abstract:
There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.

This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.

Speaker Biography:
Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
Read more >
Mar 26 2015
53 mins
Play
  • Live and recorded (79)
  • Upcoming (0)
  • Date
  • Rating
  • Views
  • Abstract:
    There is a great interest in application of human mesenchymal stem cells (hMSCs) in cell therapy and tissue engineering due to their self-renewal, multi-lineage differentiation, immunomodulation, and trophic potential. One of the challenges faced in the clinical application of hMSCs is the need for efficient expansion of these cells in vitro without altering their capacity. Serum-free mammalian cell culture media, in particular, require optimization of the expansion protocols. Even subtle changes in routine handling can have a significant impact on the cells’ potential.

    This seminar will cover the variables that can influence the desired regenerative and differentiation properties including medium selection, vessel surface treatment, impact of the cell source, and seeding density. We will also discuss how users can select the correct conditions for optimized growth and functionality.

    Speaker Biography:
    Brian Posey is a Product Development Manager for cell culture media at Corning Life Sciences. Brian has over 10 years experience in cell biology and industrial scale cGMP manufacturing of both liquid and powder cell culture media. Since joining Corning in 2012, Brian has lead numerous innovative technology projects for the media business ranging from customer technology transfer for production scale-up to developing new serum-free media for industrial and stem cell lines.
  • Abstract:
    As a key determinant of drug pharmacokinetics, transporter mediated drug-drug interaction has garnered significant attention from the pharmaceutical industry and regulatory authorities. Corning offers a comprehensive list of tools to support drug transporter studies and recently introduced Corning® TransportoCells™ products to support in vitro assessment of drug interaction with SLC transporters. This new model provides a convenient “thaw and go” cell-based model with robust activity and consistent performance. In this webinar, we will provide an overview of Corning TransportoCells products along with applications for in vitro-to-in vivo correlation. Validation data will also be presented for the newly available TransportoCells products, including OATP1A2, OATP2B1, PEPT1, PEPT2, and NTCP.

    Presenter Biography:
    Dr. Na Li received her B.S degree in Biology from Fudan University, Shanghai, China, and her Ph.D. in Pharmacology from Dartmouth Medical School, Hanover, NH. Her major research focus is on drug transporters, including interspecies differences in hepatobiliary transporters, transporter quantification, and in vitro-to-in vivo extrapolation of drug pharmacokinetics. At Corning, Dr. Li contributes her expertise in in vitro drug transporter technology and its application in drug ADME.
  • Join us on January 28th for a special Corning-sponsored webinar presented by ATCC®.

    Abstract:
    The significance of 3D tissue modeling opens up new possibilities for the study of complex physiological processes in vitro. Advances in cell isolation, media development, substrates, and growth surfaces are leading to culture environments that provide better biological and functional properties than traditional 2D cell culture. These models may provide a more predictive analysis and result in a more streamlined process of drug discovery and development. In this webinar, we will discuss recent developments in 3D modeling using ATCC primary and hTERT immortalized cells with specialized Corning® permeable support culture systems in dermatologic and respiratory studies.

    Presenter Biography:
    Dr. Yukari Tokuyama is a Field Application Scientist at ATCC. Prior to this role, she led the Stem Cell Product Development group and focused on products for human induced pluripotent stem cells and lineage specific differentiation. She earned her Ph.D. in Cell and Molecular Biology from the College of Medicine at the University of Cincinnati, where she studied the mechanism of genomic instability in cancer. She completed her post-doctoral training at the Oregon Health & Science University, Oregon National Primate Research Center, with a research focus on human and non-human primate stem cell biology.
  • Join us for a special Corning sponsored webinar presented by Promega Corporation.

    Cells cultured in 3D model systems often acquire relatively large in vivo-like structures compared to the thickness of a 2D monolayer of cells grown on standard plastic plates. Multicellular 3D culture systems containing more than one cell type and exhibiting formation of a complex extracellular matrix represent a more physiologically relevant environment, yet provide a challenge for assay chemistries originally designed for measuring events from monolayers of cells. There is an unmet need for guidelines for design and verification of convenient and effective assays useful for larger 3D microtissues. Critical factors to consider for each model system and cell type include effective penetration of detection reagents and/or complete lysis of microtissue structures using combinations of detergent and physical disruption. We will present the approach used to verify performance of a bioluminescent ATP detection assay for measuring cell viability, a caspase assay for detecting apoptosis, and cell stress reporter assays to detect mechanisms leading to cytotoxicity. Recommendations for factors to consider when verifying performance of cell health assays on 3D culture models will be presented.

    Speaker Bio:

    Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has since held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also led efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Specialist, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models.
  • Primary cells can more closely mimic an in vivo-like state and generate more physiologically relevant data than immortalized cells. But unlike immortalized cells, primary cells have complex nutritional needs and require optimized growth conditions. In this webinar, you will learn:
    •Proven techniques for isolating primary cells from tissues
    •The importance of choosing the correct dissociation method
    •Troubleshooting techniques for culturing healthier primary cells.
    •Other topics to be discussed include:
    -Choosing the optimal cell culture surface
    -Selecting the optimal cell culture media 
    -Choosing the correct vessel for scaling-up
  • Angiogenesis is the process by which a new blood supply is established from pre-existing blood vessels. It is initiated by degradation of vessel basement membrane, endothelial cell proliferation, invasion, and directional migration towards chemoattractants, tube formation, and finally the establishment of a new vasculature.

    We will discuss a portfolio of Corning products designed to investigate specific stages of angiogenesis through standardized and quantitative in vitro cell-based assays.

    •HUVEC-2 Endothelial Cells—Widely studied endothelial cells that have been pre-screened for responsiveness to VEGF, a prototypic stimulator of angiogenesis
    •ECMs and Chemoattractants—ECMs and key pro-angiogenic chemoattractants for optimal EC propagation, attachment, differentiation, and other key functions
    •Endothelial Cell Invasion and Migration Assays—An enabling platform technology consisting of Corning® FluoroBlok™ microporous permeable supports coated with our unique extracellular matrix proteins for quantitation of endothelial cell migration and invasion
    •Endothelia Cell Tube Formation Assay—A rapid assay system allowing direct screening of angiogenic compounds for their effects on endothelial cell tube formation


    Biography:

    Paula Flaherty is a Technology Manager at Corning Life Sciences. Her team develops strategy and products focused on the modulation of in vitro cell behavior using extracellular matrix, media, vessel design, and growth factors. Prior to joining Corning Life Sciences, Paula studied retinal degeneration at the Berman-Gund Laboratory, Harvard Medical School in Boston, MA. She received her bachelor’s degree in Microbiology from the State University of New York and is an In Vitro Cell Biology Fellow, W. Alton Jones Cell Science Center in Lake Placid, NY.
  • Are you relying on biochemical and cell based in vitro assays in your research? In this webinar, Dr. Mark Rothenberg will share “insider” tips and tricks for enhancing your biochemical and cell-based assay performance.
    Critical parameters for achieving success with these assays include understanding the assay dynamics, the instrumentation involved in reading the assay, and, in the case of cell-based assays, the environment in which the cells are grown impacts cellular physiology. Factors such as microplate geometry, density, surfaces, and instrumentation all play important roles in the success of the assay.
    Learn how to:
    •Select the correct microplate and its role in the success of the assay
    •Choose the correct tip for your liquid handling needs
    •Determine the correct instrumentation and settings to run your assay
  • In the past several decades, the usage of mammalian cell culture processes have allowed for better understanding of basic research and manufacturing of higher quality products compared to previous methods. Although much progress has been developed throughout the years, limitations and challenges during optimization of such processes in scale-up of mammalian cell cultures may be encountered.

    This webinar will provide a simple guide and review of novel cell culture vessels and surface technologies that have enabled researchers to improve suspension and adherent mammalian cell culture scale-up. Additionally, this webinar will cover certain parameters to consider when scaling-up cells. Selecting the correct vessel and cell culture conditions will increase throughput without increasing laboratory space, incubator space, or time.
  • Extensive genomic sequencing efforts in recent years have provided detailed profiles of the somatic gene mutations that occur in a wide range of human cancers. In order to facilitate basic and translational cancer research, ATCC has designed and validated a number of genetic alteration cell panels targeting the key molecular pathways identified in these studies. To demonstrate suitability of the panels for high throughput screening, the EGFR panel was selected for evaluation using Corning® Epic® Technology, a label-free platform that uses optical biosensors for high sensitivity biochemical and cell-based assays.
    Label-free dynamic mass redistribution (DMR) responses in whole cells provide phenotypic activity profiles which are readily amenable to evaluation of compound activity and pharmacology. DMR responses obtained using the EGFR cell panel showed that Epic Technology can be utilized to evaluate receptor responsiveness to ligands and successfully predict drug response. Furthermore, label-free phenotypic responses can provide profiles of cellular signaling pathways downstream of receptor activation that may identify alternative targets for drug screening in the cell panel. In summary, combining Epic Technology and the EGFR genetic alternation panel offers convenient tools to screen for ligands or biologics that directly target or affect EGFR receptor biology.
  • In this webinar, you will learn why partnering with Corning® GentestSM Contract Research will enable your company to reach goals faster. You will also learn about our latest service offerings, including new CYP induction and SLC transporter assay services - all designed to align with regulatory agency guidance documents. These services continue to strengthen our in vitro drug-drug interaction testing portfolio with a deep focus on enzyme inhibition, induction, and transport.

Embed in website or blog